Unlocking the Value of Biosimilars: Challenges and Solutions

By Staff Writer

August 10, 2023

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has recently published a report highlighting the gaps and challenges in the value assessment of biosimilars.

The report brings to light the ongoing debate on how to accurately assess the value of biosimilars, especially when they request reimbursement for the same indication as the reference biologic. The report also touches upon the different regulatory requirements for biosimilars across various jurisdictions.

The aim of this review is to provide an overview of the existing challenges and propose potential approaches to address them. This could pave the way for improved methodologies in economic evaluation and better access to these therapies in different jurisdictions.

Assessing the value of a biosimilar, a biological product highly similar to an already approved biological product, can be done through either a price comparison or a full economic evaluation. The choice of method depends on factors such as the relative efficacy of the reference biologic and the biosimilar, indication extrapolation, and value assessment in biologic-naive and biologic-experienced patients. A price comparison is typically used when the two products differ significantly in terms of costs, but not effectiveness. However, a full economic evaluation is required when the reference biologic is not reimbursed, has not been appraised, or is not the standard of care. Some countries, such as Belgium, France, and the Netherlands, classify biosimilars as products with no added therapeutic value compared to the reference biologic. Therefore, they have implemented an abbreviated pricing and reimbursement pathway for biosimilars. The value assessment of a biosimilar is a dynamic process and may need to be revisited as new evidence emerges.

The ISPOR Special Interest Group on Biosimilars is committed to generating new insights in this field by interviewing experts at Health Technology Assessment (HTA) agencies worldwide.

For the full report follow the link below.

Reference url

Recent Posts

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

HPV testing HNSCC
    

HPV Testing in Head and Neck Squamous Cell Carcinoma

🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?

Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.

Look into this essential topic and see how these insights could revolutionize clinical practices.

#SyenzaNews #oncology #HealthTech #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.